
    
      This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and
      dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics
      and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when
      administered as a single agent or combined with chemotherapy.
    
  